These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 8515496)
1. Brief weekly chemotherapy for elderly patients with intermediate-grade or high-grade non-Hodgkin's lymphoma. Inanç SE; Onat H J Natl Cancer Inst; 1993 Jul; 85(13):1088-9. PubMed ID: 8515496 [No Abstract] [Full Text] [Related]
2. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma. Zelenetz AD Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):21-6. PubMed ID: 14682115 [TBL] [Abstract][Full Text] [Related]
3. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Balducci L; Repetto L Cancer; 2004 Jan; 100(1):6-11. PubMed ID: 14692018 [No Abstract] [Full Text] [Related]
4. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W; Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651 [TBL] [Abstract][Full Text] [Related]
5. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma. Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911 [TBL] [Abstract][Full Text] [Related]
6. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Blayney DW; McGuire BW; Cruickshank SE; Johnson DH Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216 [TBL] [Abstract][Full Text] [Related]
7. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959 [TBL] [Abstract][Full Text] [Related]
8. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Tirelli U; Balzarotti M; Uziel L; Ferreri AJ; Santoro A; Spina M Ann Oncol; 2006 Mar; 17(3):533. PubMed ID: 16291585 [No Abstract] [Full Text] [Related]
9. VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly. Zinzani PL; Bendandi M; Gherlinzoni F; Mazza P; Salvucci M; Aitini E; Miggiano MC; Gozzetti A; Tura S Haematologica; 1993; 78(6):378-82. PubMed ID: 7513674 [TBL] [Abstract][Full Text] [Related]
10. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071 [TBL] [Abstract][Full Text] [Related]
11. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. Blay JY; Chauvin F; Le Cesne A; Anglaret B; Bouhour D; Lasset C; Freyer G; Philip T; Biron P J Clin Oncol; 1996 Feb; 14(2):636-43. PubMed ID: 8636781 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma. Abbasi MR; Sparano JA; Sarta C; Wiernik PH Med Oncol; 2003; 20(1):53-8. PubMed ID: 12665685 [TBL] [Abstract][Full Text] [Related]
13. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma. Fukuno K; Tsurumi H; Ando N; Kanemura N; Goto H; Tanabashi S; Okamoto K; Moriwaki H Int J Hematol; 2006 Oct; 84(3):242-7. PubMed ID: 17050199 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of elderly patients with non-Hodgkin's lymphoma]. Titorenko IB; Kriachok IA Lik Sprava; 2011; (5-6):79-85. PubMed ID: 22606896 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype. Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583 [TBL] [Abstract][Full Text] [Related]
16. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Lyman GH; Delgado DJ Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075 [TBL] [Abstract][Full Text] [Related]
17. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. Smalley RV; Andersen JW; Hawkins MJ; Bhide V; O'Connell MJ; Oken MM; Borden EC N Engl J Med; 1992 Nov; 327(19):1336-41. PubMed ID: 1406835 [TBL] [Abstract][Full Text] [Related]
18. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group. Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465 [TBL] [Abstract][Full Text] [Related]